National Cancer Institute - NCI Division of Cancer Treatment and ...

National Cancer Institute.
discovery of new, rationally based and
natural source–derived anticancer treatments
and strategies. Through funding
provided under a request for applications
(RFA) (http://grants.nih.gov/grants/guide/
rfa-files/RFA-CA-05-001.html), which
expired in May 2004, the NCDDG supports
13 multidisciplinary groups in the discovery
of new anticancer drugs.
This program is one of the first examples
of NCI partnering with private industry.
The NCDDG program has assisted in the
development of four FDA-approved anticancer
agents: topotecan, NSC 609699
(Hycamtin®); Gliadel® Wafers, NSC 714372;
denileukin diftitox, NSC 733971 (Ontak®);
and cetuximab, NSC 714692 (Erbitux®).
The Biological Resources Branch has
been instrumental in the production
of vaccines and other biologic agents,
especially for NCDDGs that lacked a
major industrial partner.
102 ■ P R O G R A M A C C O M P L I S H M E N T S 2 0 0 6
■ ■ ■
Translating promising target-directed compounds
into drugs for human use is an exacting task that
requires very specific, interrelated activities.
Gliadel® Wafers being implanted in the brain at the site of a resected tumor.
DTP’s NCDDG helped develop this new form of carmustine, a successful
anticancer agent.
Although NCDDG projects do not support
clinical trials, timely clinical evaluation
of agents discovered through NCDDG is
encouraged.
No new applications for this program are
being accepted at this time.
Drug Development
Rapid Access to Intervention
Development—for Academics
http://dtp.nci.nih.gov/docs/raid/
raid_index.html
Contact:
Coordinator, RAID Program
301-496-8720, raid@dtpax2.ncifcrf.gov
Translating promising target-directed
compounds into drugs for human use is
an exacting task that requires very specific,
interrelated activities. NCI supports this
critical arm of drug development through
a variety of initiatives, including DTP’s
Rapid Access to Intervention Development
(RAID) program.
RAID provides preclinical drug and biologic
development resources to academic investigators
who want to conduct their own
clinical trials. Once an optimal compound
is selected via R·A·N·D or another discovery
path, RAID facilitates further preclinical
development.
Since its inception in 1998, the RAID program
has approved 104 projects, through
which 13 small molecules and 11 biologic
agents later entered clinical trials.
The goal of RAID is to provide clinical
proof of principle that a new molecule
or approach is a viable candidate for